NC
AVIR icon

NewSquare Capital’s Atea Pharmaceuticals AVIR Stock Holding History

NewSquare Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8
Closed -$30 – 622
2023
Q2 		$30 Hold
8
– – ﹤0.01% 829
2023
Q1 		$27 Hold
8
– – ﹤0.01% 863
2022
Q4 		$38 Buy
+8
New +$40 ﹤0.01% 800

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewSquare Capital's AVIR Position: Q3 2023 in Review

NewSquare Capital sold out of Atea Pharmaceuticals (AVIR) in Q3 2023, closing a stake of 8 shares — an estimated $30 sold.

NewSquare Capital first reported a position in AVIR in Q4 2022 and held it in 3 quarters. The position peaked at $38 in Q4 2022. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

  • NewSquare Capital reported no remaining Atea Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 8 Atea Pharmaceuticals shares in Q3 2023, an estimated $30.
  • NewSquare Capital first reported a position in Atea Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Atea Pharmaceuticals position peaked at $38 in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.